| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.2174/157016207782418443 |
| P698 | PubMed publication ID | 18045117 |
| P50 | author | Dennis R. Burton | Q56331320 |
| P2093 | author name string | Michael B Zwick | |
| P433 | issue | 6 | |
| P921 | main subject | HIV | Q15787 |
| vaccine engineering | Q14861085 | ||
| vaccine | Q134808 | ||
| P304 | page(s) | 608-624 | |
| P577 | publication date | 2007-11-01 | |
| P1433 | published in | Current HIV Research | Q5195049 |
| P1476 | title | HIV-1 neutralization: mechanisms and relevance to vaccine design | |
| P478 | volume | 5 |
| Q36363866 | A novel assay for antibody-dependent cell-mediated cytotoxicity against HIV-1- or SIV-infected cells reveals incomplete overlap with antibodies measured by neutralization and binding assays |
| Q33653774 | A rev1-vpu polymorphism unique to HIV-1 subtype A and C strains impairs envelope glycoprotein expression from rev-vpu-env cassettes and reduces virion infectivity in pseudotyping assays |
| Q30843874 | Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics. |
| Q24655932 | Antibody recognition of a highly conserved influenza virus epitope |
| Q33946158 | Antibody to gp41 MPER alters functional properties of HIV-1 Env without complete neutralization |
| Q33762505 | Benchmarking B-cell epitope prediction for the design of peptide-based vaccines: problems and prospects |
| Q37318042 | Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation |
| Q37334851 | Complementation of diverse HIV-1 Env defects through cooperative subunit interactions: a general property of the functional trimer |
| Q33874652 | Dendritic cell-based human immunodeficiency virus vaccine |
| Q38817990 | Dense Array of Spikes on HIV-1 Virion Particles |
| Q27003380 | Distinct roles of CD4+ T cell subpopulations in retroviral immunity: lessons from the Friend virus mouse model |
| Q34576055 | Enhanced mucosal immune responses to HIV virus-like particles containing a membrane-anchored adjuvant |
| Q39454698 | Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors |
| Q38754324 | First Membrane Proximal External Region-Specific Anti-HIV1 Broadly Neutralizing Monoclonal IgA1 Presenting Short CDRH3 and Low Somatic Mutations |
| Q28743199 | Functional stability of unliganded envelope glycoprotein spikes among isolates of human immunodeficiency virus type 1 (HIV-1) |
| Q35582579 | Glycans flanking the hypervariable connecting peptide between the A and B strands of the V1/V2 domain of HIV-1 gp120 confer resistance to antibodies that neutralize CRF01_AE viruses |
| Q39344552 | HIV gp120 H375 is unique to HIV-1 subtype CRF01_AE and confers strong resistance to the entry inhibitor BMS-599793, a candidate microbicide drug. |
| Q47841328 | HIV pseudovirion vaccine exposing Env "fusion intermediates"-response to immunisation in human CD4/CCR5-transgenic rats |
| Q35745442 | Immunogenic Display of Purified Chemically Cross-Linked HIV-1 Spikes |
| Q34125906 | In Vivo Mechanisms of Vaccine-Induced Protection against HPV Infection |
| Q43170883 | In silico vaccine design based on molecular simulations of rhinovirus chimeras presenting HIV-1 gp41 epitopes |
| Q33725718 | In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1 |
| Q34611144 | Increased functional stability and homogeneity of viral envelope spikes through directed evolution |
| Q37910841 | Limitations to the structure-based design of HIV-1 vaccine immunogens |
| Q34681455 | MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1. |
| Q37419199 | Modeling virus- and antibody-specific factors to predict human immunodeficiency virus neutralization efficiency. |
| Q27651385 | Molecular architecture of native HIV-1 gp120 trimers |
| Q91582856 | Neutralization and beyond: Antibodies and HIV-1 acquisition |
| Q42170072 | Nonneutralizing HIV-1 gp41 envelope cluster II human monoclonal antibodies show polyreactivity for binding to phospholipids and protein autoantigens |
| Q34309493 | Partial rescue of V1V2 mutant infectivity by HIV-1 cell-cell transmission supports the domain's exceptional capacity for sequence variation |
| Q34225659 | Requirements for empirical immunogenicity trials, rather than structure-based design, for developing an effective HIV vaccine |
| Q38046828 | Role of human immunodeficiency virus type 1 envelope structure in the induction of broadly neutralizing antibodies. |
| Q36184440 | Saturation Mutagenesis of the HIV-1 Envelope CD4 Binding Loop Reveals Residues Controlling Distinct Trimer Conformations |
| Q39001207 | Stable 293 T and CHO cell lines expressing cleaved, stable HIV-1 envelope glycoprotein trimers for structural and vaccine studies |
| Q45999339 | The caveolin-1 binding domain of HIV-1 glycoprotein gp41 (CBD1) contains several overlapping neutralizing epitopes. |
| Q33935016 | Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates |
Search more.